Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The company posted significant improvements in net income and earnings per share compared to the prior year.
For the fourth quarter ended December 31, 2025, Bio-Rad reported net income of $720.0 million, a turnaround from the net loss of $715.8 million in the same period of 2024. Earnings per share were $26.65, compared to a loss of $25.57 per share a year earlier.
For the full year 2025, the company achieved net income of $759.9 million, versus a net loss of $1,844.2 million in 2024. Earnings per share for the full year were $27.85, significantly higher than the loss of $65.36 per share in the prior year.
The strong financial performance was driven by gains from changes in the fair market value of equity securities and loan receivables during 2025, compared to substantial losses recorded in the previous year.
Net sales for the fourth quarter rose to $693.2 million from $667.5 million a year ago, while full-year net sales increased to $2,583.2 million from $2,566.5 million in 2024.
BIO is currently trading after market at $256.54 down $35.88 or 2.27 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.